ULK2 and central nervous system cancer: Furthermore, survival analysis revealed that patients with glioma with high expression of ADD2, CTC1, SRCIN1, VPS4A, ULK2, excluding RORA, had a longer overall survival than those with low expression (Figures 6A–F).